Crosby’s on-field production remains elite. In the 2025-26 regular season, he posted 73 total tackles, 10 sacks, 28 tackles for loss, and one interception, underscoring why he’s viewed as a premier edge rusher. The question, though, is whether Crosby’s value justifies pairing two first-round picks with a large contract.
The medical analysis surrounding Crosby has become a focal point. A doctor’s report described a significant meniscus tear along with related bone and cartilage damage in the knee. The finding suggests cartilage involvement beyond typical meniscal injury, which can complicate short- and long-term health and impact trade value and contract negotiations.
Experts indicate that articular cartilage damage raises concerns for teams considering a trade, potentially dampening interest from contenders unwilling to meet premium draft-pick costs. If the damage is newly discovered or emphasized at the latest physical, it could help explain why the Ravens canceled their deal and why the Raiders face a tougher path to finding a trade partner.
Despite Crosby’s public assertion of remaining with Baltimore’s former trade target, discussions around a return to the market could continue, particularly as draft logistics unfold. Analysts noted that the window for trade leverage tends to narrow as the draft approaches, which may influence whether Crosby is moved or kept in Las Vegas.
If a trade were to occur, the prevailing view is that Crosby’s medical concerns will temper expectations. Teams may be reluctant to meet high draft-pick prices or top-shelf salaries without assurances of sustained knee health, complicating negotiations for a marquee pass rusher.
Bottom line: Crosby’s health findings complicate the trade calculus for any potential suitor, including the Bears, and may keep him in Las Vegas longer than initially anticipated. The situation remains fluid as teams weigh medical risk against on-field impact and draft capital in the lead-up to the draft.
